This Innovative Biotech Company is Taking a Novel, Game-Changing Approach to Eradicating Many Respiratory Viruses Once and For All Including the Tripledemic Threat Of COVID, RSV, and the FLU!
NanoViricides, Inc. (NYSE American: NNVC) is a global leader in broad-spectrum antiviral nanomedicines developing drugs that work safely and effectively even against variants.
These drugs could be as revolutionary as antibiotics and do not rely on immune systems making them great for seniors and children!
Download report and stay up to date with NNVC
NV-387 - A novel broad-spectrum antiviral
NanoViricides, Inc. (NYSE American: NNVC)’s lead drug candidate is NV-387 (drug product NV-CoV-2) for the treatment of RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections.
Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field, enabling NNVC to anticipate that nanoviricide drugs could have many decades long of “life of service.”
No matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective.
Thus NV-387 and other antiviral drugs designed on the nanoviricides platform can be expected to have a long duration of effective usability against the target viruses, reaching into several decades, similar to antibiotics, but in stark contrast with current antiviral approaches.
An antiviral drug such as NV-387 if found to be effective in human clinical studies would be a highly desirable drug globally. It would enable treatment of patient as soon as they present to the physician with a viral disease without waiting for a test for identifying which viral infection it is.
This is reminiscent of how antibiotics are prescribed, without specific infectious agent identification, relying on the ultra-broad-spectrum of antibacterial activity.
Extremely Broad Antiviral Spectrum of NV-387 Resulted Because Many Diverse Viruses Use Common Host-Side Landing Sites
Over 90% of human pathogenic viruses are known to use one or more “landing sites” that are in the Sulfated Proteoglycans (“SPG”) family. A successful host-mimetic nanoviricide drug using SPG as the key feature to attract viruses could theoretically be able to attack most if not all such viruses.
NV-387 is designed to mimic SPG and attack the virus as a cell-mimicking decoy. We have accumulated substantial evidence that in lethal viral infection animal studies, NV-387 demonstrated strong antiviral activity against a range of different virus families, exceeding or matching the activity of known approved drug agents.
Superior to Other Treatments
NV-387 was substantially superior to remdesivir in coronavirus infections, using a model for SARS-CoV-2 (COVID) virus, as reported earlier. We believe that NV-387 continues to be one of the most active antiviral drugs against multiple coronaviruses, and that it is a viable clinical candidate for drug development to treat COVID, Long COVID, as well as potentially MERS, SARS, and seasonal coronavirus infections.
NV-387 was substantially superior to the three approved drugs, namely Tamiflu®, Rapivab® , and Xofluza® against an Influenza H3N2 lethal lung viral infection study, as previously reported. We believe that NV-387 is expected to possess strong antiviral activity against H5N1 “Bird Flu” as well, given that H5N1 viruses are known to bind to heparan sulfate proteoglycans, and based on the observed broad-spectrum activity of NV-387.
NV-387 was at least as good as TPOXX® in a model animal study for the development of Smallpox/Mpox drugs, in two different ways of acquiring infection, as reported earlier.
NNVC has also found that NV-387 is capable of completely curing a lethal RSV lung virus infection in animals, leading to indefinite survival of the animals, as reported recently. There is no cure for RSV, and no approved drug for treatment of RSV infection other than the toxic last-resort drug ribavirin.
Moreover, even novel viruses, whether from natural sources or bio-engineered, are expected to be susceptible to NV-387 if they employ SPG for gaining access to human cells to infect and cause disease. Thus, NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics.
NV-387 could thus be a single drug to treat all of the “tripledemic” viruses, and more, when so approved!
"Resistance is Futile" - Host-Mimetic Technology To Solve the Greatest Pain for Antiviral Medicines, i.e. Virus Escape
No matter how much a virus changes in the field, it uses the same “landing sites” in the host body to gain access to cells, attach to and then fuse into the cells, causing an infection. A drug using the same landing sites and acting as a “decoy” would remain effective against the virus even as the virus changes, because the host side does not change.
NV-387 is designed to employ such advanced “host-mimetic” technology, built into the nanoviricide™ nanomedicine that is further designed to “look like a cell” to the virus.
In contrast, vaccines, antibodies and small chemical drugs all lose their effectiveness as the virus changes in the field. The virus is constantly changing due to various natural mechanisms such as mutations, recombinations, and/or re-assortments that are native to the virus lifecycle.
Ultra-Broad-Spectrum Antiviral Nanomedicines Enabled by the Nanoviricides Platform Would Open Up Very Large Market Sizes
Even with a decline since 2022, COVID-19 continues to hospitalize and kill people in the USA – the CDC website states 69,200 hospitalizations and 2,652 deaths since January 1, 2024; the worldwide market size for COVID-19 therapeutics is expected to exceed $16.2 Billion in 2031*.
*Source: Transparency Market Research
The market size for RSV therapeutics was estimated to be $2 Billion in 2023 and is expected to rise to exceed $8.5 Billion by the year 2031**.
**Source: Growth+ Market Reports.
NANOVIRICIDES TECHNOLOGY WILL TRANSFORM THE WAY VIRUSES & THEIR VARIANTS ARE TREATED WORLDWIDE!
NNVC’s novel approach has already enabled variant-proof drugs, blocking the complete viral life cycle without requiring help from the host’s defense systems! If both the viral re-infection cycle, and viral replication cycle arms of the viral lifecycle are blocked, a cure for many viral diseases is possible!!
The Company’s virus-specific nanoviricides have been created against important viruses such as HIV, Influenza and Bird Flu by choosing highly virus-specific ligands.
Broad-spectrum nanoviricides have been created that can bind to possibly as many as 90-95% of known viruses. The Company is also developing broad-spectrum nanoviricides to combat several neglected tropical diseases, such as Dengue, Rabies, and Ebola/Marburg.
The nanoviricide technology involves copying the invariant and essential host-side signature and, using this signature, building a direct-acting antiviral that destroys the virus. This design feature of nanoviricides solves the most intractable issue in antiviral response, that of viruses escaping the vaccines, antibodies, and small chemical drugs.
NV-387 is designed using the host-side signature that over 90% of human pathogenic viruses use for creating a successful infection in the human or animal hosts. This means NV-387 is likely to be active against a large number of viruses and could be sufficiently active against many of them to become a successful clinical drug against them.
In fact, the company has already demonstrated that NV-387 is highly effective in preclinical studies against lethal RSV infection as well as against lethal Smallpox-like virus infections!
NV-387 - with Activity Against RSV
NV-387 has completed a Phase 1a/1b human clinical trial in healthy subjects with no reported adverse events even at the highest and repeated dosages.
The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.
NNVC has reported that the antiviral activity of NV-387 against RSV/A2 is strong enough to have resulted in the full survival of lethally infected animals!
In this study, extended dosing of NV-387 given orally was compared with a high dose of ribavirin given orally for the same duration. Two doses were given on first day of dosing followed by one daily dose for next 9 days (for a total of 11 doses). NV-387 given by this dosing regimen led to complete survival of the mice beyond the 21 days study period, with no signs of pathology (disease) apparent on the last day of observation. In contrast, ribavirin led to death of all animals by 14 days!
Ribavirin is the only currently approved drug for RSV infection, that can be used only as a last resort because of its extensive toxicity that limits its effectiveness.
Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure!
NanoViricides, Inc. (NYSE American: NNVC) recently revealed that the strong antiviral activity of NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV infection animal model. The animals in only the NV-387 treated group survived completely, as previously reported.
In contrast, lethally infected animals in the Ribavirin oral treatment group showed progressive lung pathology, demonstrating progressive inflammation in the lung tissue which resulted in moderate levels of inflammation as well as infected cells in the inflammatory infiltrate on day 10, increasing to severely infected lungs with alveolitis and severe pneumonia by day 13. All animals in the ribavirin-treated RSV infected group died by 14 days.
The complete survival and clear lungs indicate that NV-387 treatment completely protected the animals and could be potentially a cure for RSV infection!
There is no drug for general treatment of RSV infection at present, enabling NV-387 to be a candidate for this $1.8 Billion to $8 Billion annual market size as estimated by GrowthPlus Reports.
RSV is an important disease in infants and children less than 5 years old, as well as in older persons over 65 years old. According to the CDC, each year in the United States, RSV leads to approximately:
- 58,000-80,000 hospitalizations among children younger than 5 years old;
- 60,000-160,000 hospitalizations among adults 65 years and older;
- 6,000-10,000 deaths among adults 65 years and older; and
- 100-300 deaths in children younger than 5 years old.
Two vaccines have recently been approved for protection of persons 60+ years old from RSV infection (Arexvy®, GSK, and Abrysvo®, Pfizer).
Abrysvo was recently approved for use in pregnant women for protection of infants. Synagis (palivizumab), an antibody, as well as a new antibody, nirsevimab (Beyfortus®) have been approved by the US FDA for protection of newborn children at risk of RSV disease.
No approved treatment currently exists for RSV other than ribavirin. This means a safe and effective treatment remains an unmet medical need and offers NNVC an incredible market opportunity.
NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Also Have Activity Against H5N1 Bird Flu Virus
NNVC reported that in a lethal animal model of lung infection by Influenza A /H3N2 virus, NV-387 was found to have substantially superior antiviral effects compared to three approved anti-influenza drugs.
The company performed a lethal lung infection study of mice infected with Influenza A/H3N2 that were treated with NV-387 or one of the three approved drugs for direct comparison: Oseltamivir (Tamiflu®, Roche), Peramivir (Rapivab®, Biocryst), and Baloxivir (Xofluza®, Shionogi, Roche).
In this study, NV-387 Oral treatment led to a survival lifespan of 15 days, compared to 10 days with Oseltamivir Oral treatment, 11 days with Peramivir I.V. treatment, and 11 days with Baloxivir Oral treatment, while the vehicle-treated and untreated (infected) animals survived only 8 days!
Thus the anti-Influenza activity of NV-387 given orally was substantially superior to all three of the approved anti-influenza drugs, namely Tamiflu, Rapivab, and Xofluza.
Given the broad spectrum of antiviral activity of NV-387 against viruses in many different virus families, NNVC believes that its effectiveness against Influenza A/H3N2 is indicative of potential antiviral activity against most if not all Influenza A viruses.
A Novel Broad-Spectrum Antiviral with Activity Against Covid
COVID is here to stay, and even as the pandemic has largely subsided, the need for COVID therapeutics is in the range of tens of billions of dollars.
Long COVID also remains a problem that effective antiviral such as NV-387 could make a difference in. An estimated 17 million adults currently have long COVID.
NNVC’s Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon!
The Phase 1 clinical trial, protocol number KM-NVCoV2-001, which received approval from the regulatory agency in India for healthy as well as COVID-19 participants, was closed and completed in April by the Drug Sponsor and the company’s licensee, Karveer Meditech, Pvt. Ltd., and the CRO, PristynCR, in India.
The decision to close the clinical trial with healthy subjects study completed was taken because diligent efforts to identify suitable COVID-19 participants for the clinical trials were met with a notable absence of positive cases at the designated clinical trial sites, despite addition of a second site during January/February 2024.
Both the single ascending dose part of this clinical trial (called Phase 1a), and the subsequent multiple ascending dose part (called Phase 1b) have been completed with healthy subjects. There were no reported adverse effects, indicating excellent safety of both of the drug products, NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, at all of the dosage levels given to the subjects. The CRO is now in the process of completing database input of all of the subjects’ clinical datasets to achieve datalock for further statistical analysis.
As previously reported, NV-387, the active ingredient in the drug products in this clinical trial, has been demonstrated to possess an extremely broad effectiveness against multiple virus families in lethal animal studies evaluating NV-387
NNVC has also demonstrated that NV-387 is highly effective in preclinical studies against lethal RSV infection as well as against lethal Smallpox-like virus infections.
NanoViricides reports that in a lethal animal model of lung infection by Ectromelia virus, oral dosing with NV-387 led to an increase in lifespan of mice that was comparable to oral treatment with tecovirimat (TPOXX®, SIGA), the approved drug against Smallpox.
Read more at: https://www.miamiherald.com/press-releases/article288412389.html#storylink=cpy
Nanoviricides, Inc. is close to having a single drug NV-387 for the treatment of all of the tripledemic respiratory viruses - Coronaviruses, RSV, and Influenza A, which would be a revolutionary achievement!
Learn More about Nanoviricides, Inc. by gaining access to the latest corporate presentation
NV-387 HAS SHOWN BROAD-SPECTRUM ANTIVIRAL ACTIVITY ACROSS MULTIPLE VIRUS FAMILIES
- NV-387 was found to be as effective as ribavirin, the toxic last resort drug, against RSV infection in a lethal lung infection animal model, as reported previously. RSV is a virus particularly threatening to vulnerable infants, young children, older adults, and immunocompromised populations.
- There is no approved drug for the treatment of RSV infection, except the toxic drug ribavirin which is only indicated for very severe cases due to its severe hemotoxicity. Ribavirin, a highly toxic drug that attacks red blood cells and can cause multi-organ failures is reserved for use as a last resort only in extremely severe hospitalized cases of RSV. NV-387 was almost as active as ribavirin.
- RSV is an important pathogenic virus that can cause lethal infection in infants as well as seniors and immunocompromised persons.
- Two different vaccines against RSV have been recently approved by the US FDA, but none are for pediatric use at present. Two different antibodies have been approved as prophylactic (i.e. to prevent RSV infection) for babies, but are not approved as therapeutics (i.e. after disease occurs).
- There is no safe and effective therapeutic available for RSV. Additionally, NV-387 has been found to be extremely safe in pre-clinical studies. Thus, we believe NV-387 could be a clinical quality drug candidate for the treatment of RSV infections.
- NV-387 was as effective as the approved drug tecovitrimat (TPOXX®, SIGA), in a lethal intra-digital infection by ectromelia virus in mice. Importantly, a combined drug made from NV-387 and tecovirimat was more effective than either drug alone, indicating NV-387 “plays well” with tecovirimat and acts by a different mechanism.
- Smallpox poses a significant biodefense threat. Ectromelia virus is a native virus of mice in the poxvirus family and is one of the key animal model viruses for developing smallpox therapeutics. Tecovirimat is an approved drug for treating smallpox infection based on the FDA “Animal Rule”, and is stockpiled by the US “Strategic National Stockpile”. It was mobilized during the recent monkeypox epidemic.
- It is important to develop additional smallpox therapeutics that work well with tecovirimat and by themselves, since viruses pose the threat of drug escape by mutation; further, in a bio-terrorism scenario, a human-engineered smallpox virus resistant to existing drugs could be a potential threat.
What’s in store for biotech in 2024? Perhaps a lot of good!
As biotech stages a big comeback, NanoViricides, Inc. (NYSE American: NNVC) looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology.
NanoViricides, Inc. (NYSE American: NNVC) is a global leader in the application of nanomedicine technologies to the safe and effective treatment of viruses and their variants INCLUDING drugs against Covid-19, RSV and other respiratory viruses!
Even with a decline since 2022, COVID-19 continues to hospitalize and kill people in the USA – the CDC website states 69,200 hospitalizations and 2,652 deaths since January 1, 2024; the worldwide market size for COVID-19 therapeutics is expected to exceed $16.2 Billion in 2031*.
*Source: Transparency Market Research
The market size for RSV therapeutics was estimated to be $2 Billion in 2023 and is expected to rise to exceed $8.5 Billion by the year 2031**.
**Source: Growth+ Market Reports.
Analysts have said that the 2023 year-end spurt of biopharma mergers and acquisitions bodes well for the sector this year. The SPDR S&P Biotech ETF, which tracks the sector, had a strong November and December.
The recent AbbVie-ImmunoGen deal “may be the start of more consistent activity we will see in 2024,” RBC Capital Markets analyst Brian Abrahams wrote in a note published late recently. “We do believe we are likely past the XBI bottom and can look to somewhat improved enthusiasm for the group—in part driven by M&A—into 2024.”
AbbVie spent about $18.8 billion on two large deals in a matter of seven days.
According to an RBC Capital, the cumulative value of biopharma deals in 2023 has been $128 billion, up from $61 billion in 2022. Major acquisitions announced include Pfizer’s $43 billion deal for the cancer-focused biotech Seagen, and Merck’s $10.8 billion deal for the immunology-focused biotech Prometheus Biosciences.
RECENT COMPANY HIGHLIGHTS:
- Broad spectrum antiviral NV-387 showing promise against many virus families including and beyond Tripledemic (i.e. COVID-19, RSV, FLU).
- No adverse events in Phase I SAD and MAD studies even at the highest dose 40mg/Kg
- Found to be non-immunogenic, non-mutagenic, non-allergenic, and non-phototoxic.
- Strong safety allows use in pediatrics, adults with co-morbidities, and immune-compromised patients unlike limitations of products currently in the market.
- Developed Oral Syrup and Oral Gummies (soft solids) – good for geriatric and pediatric patients
- Drugs expected to continue to be effective even as the virus generates variants – unique receptor site doesn’t change
- Technology mimics unique receptor site used by virus; delivers to specific targets using receptor-recognition (no bulky antibodies)
- Company is currently seeking licensing and partnering opportunities for its key asset, NV-387, and its key nanoviricides™ platform technology. The Company has engaged Aagami, a small boutique firm, to help with these efforts for the regions of India and Japan, noting the firm’s strength and specialty in these regions for licensing and partnering endeavors.
ANTIBODIES AND VACCINES ARE OUTDATED: NanoViricides, Inc has a more innovative approach that works even when viruses mutate!!!
NANOVIRICIDES are better because they destroy viruses and their variants without relying on the patient's immune system, thereby making them effective for populations that include geriatric and pediatric patients..
- Antibodies only bind by two points to the virus, and destruction of the complex requires effective immune function, which is not the case in sick patients..
- Vaccines only train the body into producing antibodies against the virus in the vaccine. Antibodies and vaccines are easily overcome by viruses by mutating in the field, hence the need for annual influenza vaccine updates.
See Below for Nanoviricides' Unique, Novel, Post-Immunotherapeutic “Bind-Encapsulate-Destroy” Mechanism
NV 387 IN CLINICAL TRIALS
The drug, developed in response to the COVID-19 pandemic, demonstrated exceptional safety in clinical trials, even at the highest dose levels, with NO adverse events reported. The unique mechanism of action involves mimicking a cell membrane, encapsulating and blocking the virus.
Beyond COVID-19, the drug also displayed promising results against respiratory syncytial virus (RSV), offering a potential solution for infants and seniors where existing treatments like ribavirin may be contraindicated due to side effects.
The clinical trials involved both oral tablets and oral gummies, catering to various age groups, including pediatrics. NV 387 exhibited broad-spectrum activity against multiple strains of coronaviruses, showcasing effectiveness 10 times greater than remdesivir in preclinical studies.
The ongoing clinical trial progress and positive results position NanoViricides at the forefront of antiviral drug development, marking a significant milestone in their journey from preclinical research since 2005 to clinical trials.
The company believes that NV-387 not only binds to the virus, but fuses with the virus surface, uprooting the glycoproteins that are required for the virus to bind to the human cell (for example, the S protein, and its products S1 and S2 proteins from coronaviruses), thereby rendering the virus incapable of infecting a cell. In contrast, antibodies are only capable of covering the virus, generally incompletely, and require immune system assistance for clearing the resulting complex!
Safety of NV-387 Studied Successfully in Phase I Human Clinical Trials with No Adverse Events
NV-387 is inherently designed to be safe, by careful choice of the components of the nanoviricide polymeric chemical, and this was borne out in the company’s studies.
Leading to the human clinical trials, NNVC had found that the safety of NV-387 was demonstrated by the very large NOAEL value of 1,200mg/Kg and MTD value of 1,500mg/Kg in rats. NNVC had also found that NV-387 was non-mutagenic, non-genotoxic, non-immunogenic, and studies indicated that allergenicity was not an issue; all parameters that indicate excellent safety.
A Phase I clinical trial of NV-387 Oral Syrup and NV-387 Oral Gummies was completed successfully with no adverse events reported. The company is awaiting reports from the CRO to further elaborate on the findings.
Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect
The company has recently reported that its clinical stage lead nanoviricide broad-spectrum antiviral drug candidate, NV-387, results in an ideal flat blood concentration profile for an extended time period upon oral administration in two different animal models!
This unusual but highly desirable, extended flat time profile of blood concentration of orally given NV-387 enables sustained antiviral effect over a long period of time, allowing infrequent dosing regimens.
- The blood concentration of NV-387 increased to a peak in approximately the first hour, and then remained almost constant for eight hours or longer, thereafter, the concentration declined to reach baseline at about twelve hours; upon oral administration of a first dose of NV-387. This was found to be the case in studies involving two different animal models, namely, rats and dogs.
- After repeated doses, the plateau of the sixth dose lasted for at least 24 hours, thereafter declining to baseline at about 36 hours, in both the rat and dog animal models.
- The same plateau profile phenomenon was observed in both male and female animals, as well as in both species of animals, namely, rat and dog.
The blood concentration profile of NV-387 is indicative of the formation of a buffering reservoir of the drug in the host that releases the drug at a regular rate into the bloodstream.
The flat time profile of NV-387 indicates that even at very high doses, its blood concentration is unlikely to result in unwanted side effects!
NV-387 ADDRESSES AN UNMET MEDICAL NEED FOR BROAD-SPECTRUM, SAFE AND EFFECTIVE ANTIVIRAL DRUG THAT WORKS AGAINST MULTIPLE VIRAL THREATS
There is a significant unmet medical need for a broad-spectrum antiviral drug that is effective and useable in all segments of the population. There are substantial limitations for all currently approved COVID drugs in terms of both the eligibility of a COVID patient, and the effectiveness of the drug.
NNVC believes that the excellent safety and the distinctly different mechanism of NV-CoV-2 (NV-387) support the use of this drug across all patient populations. This is an important characteristic for a COVID drug as well as for a drug to treat RSV infection.
Discover how NV-387 acts by a novel mechanism here: https://www.nanoviricides.com/technology.html
The Strong Safety of NV-387 Is Expected to Enable Its Use Across All Patients
The strong safety and tolerability of NV-387 demonstrated in human clinical trial implies that it can be used:
- across all ages from pediatrics to seniors;
- irrespective of co-morbidities such as diabetes, other pre-existing diseases, or immune compromised status of the individual;
- and at all levels of disease severity, from mild/moderate to severe to very severe (hospitalized patients).
A Highly Effective Team with Decades of Entrepreneurial, Pharmaceutical, and Nanomedicine Experience
Anil R. Diwan, PhD
Executive Chairman, President
Dr. Diwan has been President and Chairman of the Board of the Company since its founding in 2005 Dr. Diwan spearheaded the efforts for the Company’s 2013 uplisting from the OTC Markets to NYSE-American. Dr. Diwan has led several of the Company’s financing efforts since 2010.
Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies as early as 1991. Dr. Diwan is a prolific inventor and a serial entrepreneur. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company with diverse portfolios including nanomedicines, small chemicals, device technologies, as well as informatics. He has won several NIH SBIR (small business innovation research) grant awards. Anil holds a Ph.D. from Rice University, TX, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India, and has consistently held high scholastic ranks and honors. Dr. Diwan has over 25 years of Bio-Pharmaceutical R&D experience with over 20 years as an entrepreneur.
He has several patents issued internationally resulting from three fundamental international patent applications. Under Dr. Diwan’s leadership, NanoViricides, Inc. has been able to keep both administrative and R&D costs at extremely low levels while robustly expanding the drug pipeline every year. Dr. Anil R. Diwan was recognized as “Researcher of the Year” by BusinessNewHaven, a Connecticut Area Business Journal, in 2014.
Ms. Meeta R. Vyas, MBA (Fin.), BS (Chem. Eng.)
interim Chief Financial Officer
Ms. Vyas is known as a strong leader with board level experience and successful achievements as a Senior Executive in a broad range of entities including publicly listed corporations, non-revenue generating entities, and medium to large size companies. Meeta has over twenty-five years of experience in performance and process improvement of both publicly listed companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meeta holds the distinction of being the first Indian woman to be named CEO of a publicly listed US corporation, Signature Brands, Inc., best known for “Mr. Coffee” and “Health-O-Meter” brand products. As CEO, acting COO and Vice Chairman of the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resulting in a return to profitability and growth within a short period of time. Later, as the CEO of the World-Wide Fund for Nature – India (WWF-India) and then as a Vice President of the National Audubon Society (USA), both non-revenue generating entities, Meeta successfully raised unrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a variety of performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementation plan for the highly successful information technology outsourcing program at General Electric (GE). Also at GE, Ms. Vyas ran GE Appliances’ Range Products business unit having revenues exceeding $1 Billion where her team doubled operating income in less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companies in chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations, and logistics operations. Meeta is married to NanoViricides, Inc. President and Chairman Anil R. Diwan.
Ms. Vyas holds a MBA in Finance from Columbia University’s Graduate School of Business, and a BS in Chemical Engineering from the Massachusetts Institute of Technology.
NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.
THE BOTTOM LINE
With its ongoing expansion and development of their diverse and promising product pipeline, NanoViricides, Inc. (NYSE: NNVC) is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.
NV-387 Could Revolutionize Antiviral Treatment Just as Antibiotics Did Against Bacteria!
The success of penicillin led to an explosion in development of antibacterials that use the same mechanism of action and provide additional benefits, stronger activity against certain bacteria and oral administration amongst them.
In fact, the world continues to use amoxicillin to treat most pediatric and adult bacterial infections to this day, some 65 years since its discovery in 1958! This durability is a direct result of the fact that most of the bacteria it attacks have not escaped the drug and have remained susceptible even after such a long time of common use.
NNVC has been able to develop NV-387 already for oral administration, as well as for injectable and inhalation formulations to enable many modes of use.
This comparison of features of nanoviricides technology platform and, in particular, NV-387, with the revolutionary antibiotics development against bacteria argues that NanoViricides (NYSE: NNVC) is now on a solid footing to revolutionize treatment of antiviral infections.
There is no denying that the world is changing… viruses are becoming more rampant. NNVC, an exciting NYSE company that is ahead of the problem, could see unstoppable growth ahead!
The company has sufficient funds to complete the on-going human clinical trials for its lead drug candidate NV-CoV-2 which is the drug product based on its “nanoviricide” active pharmaceutical ingredient (“API”), NV-387.
The successes of NV-387 as a broad-spectrum antiviral bode well for validating the multiple modalities in which NNVC’s Nanoviricides Platform Technology can be employed to revolutionize the treatment of viral infections as well as pandemic preparedness response.
Start your research today!
This year the company has a focus on advancing NV-387 through further clinical trials, expanding its treatment capabilities to address unmet medical needs. This includes RSV, the flu, and other viruses.
NanoViricides, Inc.’s innovative platform technology, R&D agility, flexible cGMP compliant facility, highly effective management team, and extensive anti-viral experience should place this company at the top of your “invest” watchlist!
Learn More about Nanoviricides, Inc. by gaining access to the latest corporate presentation
Disclaimer
AmplifyIR, Inc (d/b/a “Financial Markets Daily”), hereinafter referred to as “AmplifyIR,” and their affiliates and control persons (the “Publisher”) are in the business of publishing favorable information and/or advertisements (the “Information”) about the securities of publicly traded companies (each an “Issuer” or collectively the “Issuers”) in exchange for compensation (the “Campaigns”). Persons receiving the Information are referred to as the “Recipients.” The person or entity paying the Publisher for the Campaign is referred to herein as the “Paying Party”. The Paying Party may be an Issuer, an affiliated or non-affiliate shareholder of an Issuer, or another person hired by the Issuer or an affiliate or non-affiliate shareholder of the Issuer. The nature and amount of compensation paid to the Publisher for the Campaign and creating and/or publishing the Information about each Issuer is set forth below under the heading captioned, “Compensation”.
This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment.
Nothing on this website should be considered personalized financial advice. Any investments recommended herein should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.
AmplifyIR, its managers, its employees, affiliates, and assigns (collectively the “Publisher”) do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above.
Release of Liability: through use of this website, viewing or using you agree to hold AmplifyIR, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. AmplifyIR encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the company profiled or is available from public sources and AmplifyIR makes no representations, warranties, or guarantees as to the accuracy or completeness of the disclosure by the profiled company. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, AmplifyIR strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. AmplifyIR’s full disclosure is to be read and fully understood before using AmplifyIR’s website, or joining AmplifyIR’s email or text list. From time to time, AmplifyIR’s will disseminate information about a company via website, email, sms, and other points of media. By viewing AmplifyIR’s website and/or reading AmplifyIR’s email or text newsletter you are agreeing to this —-> https://financialmarketsdaily.com/disclaimer/. All potential percentage gains discussed in any communications are based on calculations from the low to the high of the day. We are engaged in the business of marketing and advertising companies for monetary compensation.
If you have questions or concerns about a product you’ve seen in one of our emails, emails, text newsletters or SMS, we encourage you to reach out to that company directly.
Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by the owner of AmplifyIR. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to AmplifyIR. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here.
COMPENSATION
NanoViricides, Inc. (NYSE: NNVC) is a client of TraDigital Marketing Group, Inc. NNVC has a 7-day agreement in place signed May 8, 2024 to May 14, 2024 to compensate TraDigital Marketing Group, Inc. $160,000 for publicly disseminating information about NNVC via website, email, and SMS. TraDigital Marketing Group, Inc. does not own any shares in NNVC. To read TraDigital Marketing Group’s full disclaimer on compensation, please go to https://tradigitalir.com/disclaimers/nnvc-disclosure/
TraDigital Marketing Group, Inc. has previously paid Interactive Offers LLC $209,000 cash for previous marketing campaigns concerning NNVC. Owners of TraDigital Marketing Group, Inc. are affiliated with AmplifyIR which owns Interactive Offers, LLC and Financial Markets Daily.
Interactive Offers LLC has been paid $648,000 cash via Bank wire transfer from NNVC for marketing efforts regarding NNVC since 5/15/2024.
